Motoneurone Disease Stroke Peripheral Neuropathy Multiple Sclerosis Lennox-Gastaut Eye Diseases
Drug Platform Discovery Pharmacokinetics Pharmacodynamic Publications
Our Mission Directors
Press Releases

Preliminary Pharmacokinetics and Drug StabilityDrug Stability

  • Research done to date indicates that NRP2945 has excellent solubility in aqueous buffers and very long shelf-life stability when stored as lyophilisate under freezing conditions. A developed proprietary liquid formulation (SC-injectable for ready injection) provides stability for 6 weeks under refrigerated conditions.
  • NRP2945 has a very low probability for human toxicity because the peptide is active in the ng/kg to μg/kg range in rodents.
  • Dosing only necessary as peripheral administration (SC) with potential long interval dosage
  • Biological efficacy (like improvement of motor scores and attenuation of weight loss during neurodegenerative bouts of disease) can be seen without necessity of time consuming “built-up” drug titres in the blood stream because mechanism of action is facilitated by hit-and-run effect after crossing of NRP2945 through the blood brain barrier.

Click on the following aspects of the NRP drug platform to read more:

Go To:

Contact Us About Us Research Target Diseases Investors